Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ...

We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

In Q4, Dupixent grew by 16% from strong prescription ... of Inhibrx as well as our value proposition to shareholders in the form of a growing dividend. Our net debt-to-EBITDA ratio, which is ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

It may cause side effects similar to those of Dupixent. Phototherapy, or light therapy, involves treatment with different wavelengths of ultraviolet light. The most common form doctors recommend ...

KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the ... Sanofi and Regeneron’s Dupixent (dupilumab) has already built a blockbuster presence as an injected ...